Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.

Yuukou Kitagawa, Hiroya Takeuchi, Y. Takagi, Shoji Natsugoe, Masanori Terashima, Nozomu Murakami, Takashi Fujimura, Hironori Tsujimoto, Hideki Hayashi, Nobunari Yoshimizu, Akinori Takagane, Yasuhiko Mohri, Kazuhito Nabeshima, Yoshikazu Uenosono, Shinichi Kinami, Junichi Sakamoto, Satoshi Morita, Takashi Aikou, Koichi Miwa, Masaki Kitajima

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Complicated gastric lymphatic drainage potentially undermines the utility of sentinel node (SN) biopsy in patients with gastric cancer. Encouraged by several favorable single-institution reports, we conducted a multicenter, single-arm, phase II study of SN mapping that used a standardized dual tracer endoscopic injection technique. Patients with previously untreated cT1 or cT2 gastric adenocarcinomas < 4 cm in gross diameter were eligible for inclusion in this study. SN mapping was performed by using a standardized dual tracer endoscopic injection technique. Following biopsy of the identified SNs, mandatory comprehensive D2 or modified D2 gastrectomy was performed according to current Japanese Gastric Cancer Association guidelines. Among 433 patients who gave preoperative consent, 397 were deemed eligible on the basis of surgical findings. SN biopsy was performed in all patients, and the SN detection rate was 97.5% (387 of 397). Of 57 patients with lymph node metastasis by conventional hematoxylin and eosin staining, 93% (53 of 57) had positive SNs, and the accuracy of nodal evaluation for metastasis was 99% (383 of 387). Only four false-negative SN biopsies were observed, and pathologic analysis revealed that three of those biopsies were pT2 or tumors > 4 cm. We observed no serious adverse effects related to endoscopic tracer injection or the SN mapping procedure. The endoscopic dual tracer method for SN biopsy was confirmed as safe and effective when applied to the superficial, relatively small gastric adenocarcinomas included in this study.

Original languageEnglish
Pages (from-to)3704-3710
Number of pages7
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume31
Issue number29
Publication statusPublished - 2013 Oct 10

Fingerprint

Multicenter Studies
Stomach Neoplasms
Japan
Stomach
Adenocarcinoma
Biopsy
Injections
Drainage
cyhalothrin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sentinel node mapping for gastric cancer : a prospective multicenter trial in Japan. / Kitagawa, Yuukou; Takeuchi, Hiroya; Takagi, Y.; Natsugoe, Shoji; Terashima, Masanori; Murakami, Nozomu; Fujimura, Takashi; Tsujimoto, Hironori; Hayashi, Hideki; Yoshimizu, Nobunari; Takagane, Akinori; Mohri, Yasuhiko; Nabeshima, Kazuhito; Uenosono, Yoshikazu; Kinami, Shinichi; Sakamoto, Junichi; Morita, Satoshi; Aikou, Takashi; Miwa, Koichi; Kitajima, Masaki.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 31, No. 29, 10.10.2013, p. 3704-3710.

Research output: Contribution to journalArticle

Kitagawa, Y, Takeuchi, H, Takagi, Y, Natsugoe, S, Terashima, M, Murakami, N, Fujimura, T, Tsujimoto, H, Hayashi, H, Yoshimizu, N, Takagane, A, Mohri, Y, Nabeshima, K, Uenosono, Y, Kinami, S, Sakamoto, J, Morita, S, Aikou, T, Miwa, K & Kitajima, M 2013, 'Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, no. 29, pp. 3704-3710.
Kitagawa, Yuukou ; Takeuchi, Hiroya ; Takagi, Y. ; Natsugoe, Shoji ; Terashima, Masanori ; Murakami, Nozomu ; Fujimura, Takashi ; Tsujimoto, Hironori ; Hayashi, Hideki ; Yoshimizu, Nobunari ; Takagane, Akinori ; Mohri, Yasuhiko ; Nabeshima, Kazuhito ; Uenosono, Yoshikazu ; Kinami, Shinichi ; Sakamoto, Junichi ; Morita, Satoshi ; Aikou, Takashi ; Miwa, Koichi ; Kitajima, Masaki. / Sentinel node mapping for gastric cancer : a prospective multicenter trial in Japan. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 ; Vol. 31, No. 29. pp. 3704-3710.
@article{acc36ed00b7e412db6f5a20ec009ea96,
title = "Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.",
abstract = "Complicated gastric lymphatic drainage potentially undermines the utility of sentinel node (SN) biopsy in patients with gastric cancer. Encouraged by several favorable single-institution reports, we conducted a multicenter, single-arm, phase II study of SN mapping that used a standardized dual tracer endoscopic injection technique. Patients with previously untreated cT1 or cT2 gastric adenocarcinomas < 4 cm in gross diameter were eligible for inclusion in this study. SN mapping was performed by using a standardized dual tracer endoscopic injection technique. Following biopsy of the identified SNs, mandatory comprehensive D2 or modified D2 gastrectomy was performed according to current Japanese Gastric Cancer Association guidelines. Among 433 patients who gave preoperative consent, 397 were deemed eligible on the basis of surgical findings. SN biopsy was performed in all patients, and the SN detection rate was 97.5{\%} (387 of 397). Of 57 patients with lymph node metastasis by conventional hematoxylin and eosin staining, 93{\%} (53 of 57) had positive SNs, and the accuracy of nodal evaluation for metastasis was 99{\%} (383 of 387). Only four false-negative SN biopsies were observed, and pathologic analysis revealed that three of those biopsies were pT2 or tumors > 4 cm. We observed no serious adverse effects related to endoscopic tracer injection or the SN mapping procedure. The endoscopic dual tracer method for SN biopsy was confirmed as safe and effective when applied to the superficial, relatively small gastric adenocarcinomas included in this study.",
author = "Yuukou Kitagawa and Hiroya Takeuchi and Y. Takagi and Shoji Natsugoe and Masanori Terashima and Nozomu Murakami and Takashi Fujimura and Hironori Tsujimoto and Hideki Hayashi and Nobunari Yoshimizu and Akinori Takagane and Yasuhiko Mohri and Kazuhito Nabeshima and Yoshikazu Uenosono and Shinichi Kinami and Junichi Sakamoto and Satoshi Morita and Takashi Aikou and Koichi Miwa and Masaki Kitajima",
year = "2013",
month = "10",
day = "10",
language = "English",
volume = "31",
pages = "3704--3710",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

TY - JOUR

T1 - Sentinel node mapping for gastric cancer

T2 - a prospective multicenter trial in Japan.

AU - Kitagawa, Yuukou

AU - Takeuchi, Hiroya

AU - Takagi, Y.

AU - Natsugoe, Shoji

AU - Terashima, Masanori

AU - Murakami, Nozomu

AU - Fujimura, Takashi

AU - Tsujimoto, Hironori

AU - Hayashi, Hideki

AU - Yoshimizu, Nobunari

AU - Takagane, Akinori

AU - Mohri, Yasuhiko

AU - Nabeshima, Kazuhito

AU - Uenosono, Yoshikazu

AU - Kinami, Shinichi

AU - Sakamoto, Junichi

AU - Morita, Satoshi

AU - Aikou, Takashi

AU - Miwa, Koichi

AU - Kitajima, Masaki

PY - 2013/10/10

Y1 - 2013/10/10

N2 - Complicated gastric lymphatic drainage potentially undermines the utility of sentinel node (SN) biopsy in patients with gastric cancer. Encouraged by several favorable single-institution reports, we conducted a multicenter, single-arm, phase II study of SN mapping that used a standardized dual tracer endoscopic injection technique. Patients with previously untreated cT1 or cT2 gastric adenocarcinomas < 4 cm in gross diameter were eligible for inclusion in this study. SN mapping was performed by using a standardized dual tracer endoscopic injection technique. Following biopsy of the identified SNs, mandatory comprehensive D2 or modified D2 gastrectomy was performed according to current Japanese Gastric Cancer Association guidelines. Among 433 patients who gave preoperative consent, 397 were deemed eligible on the basis of surgical findings. SN biopsy was performed in all patients, and the SN detection rate was 97.5% (387 of 397). Of 57 patients with lymph node metastasis by conventional hematoxylin and eosin staining, 93% (53 of 57) had positive SNs, and the accuracy of nodal evaluation for metastasis was 99% (383 of 387). Only four false-negative SN biopsies were observed, and pathologic analysis revealed that three of those biopsies were pT2 or tumors > 4 cm. We observed no serious adverse effects related to endoscopic tracer injection or the SN mapping procedure. The endoscopic dual tracer method for SN biopsy was confirmed as safe and effective when applied to the superficial, relatively small gastric adenocarcinomas included in this study.

AB - Complicated gastric lymphatic drainage potentially undermines the utility of sentinel node (SN) biopsy in patients with gastric cancer. Encouraged by several favorable single-institution reports, we conducted a multicenter, single-arm, phase II study of SN mapping that used a standardized dual tracer endoscopic injection technique. Patients with previously untreated cT1 or cT2 gastric adenocarcinomas < 4 cm in gross diameter were eligible for inclusion in this study. SN mapping was performed by using a standardized dual tracer endoscopic injection technique. Following biopsy of the identified SNs, mandatory comprehensive D2 or modified D2 gastrectomy was performed according to current Japanese Gastric Cancer Association guidelines. Among 433 patients who gave preoperative consent, 397 were deemed eligible on the basis of surgical findings. SN biopsy was performed in all patients, and the SN detection rate was 97.5% (387 of 397). Of 57 patients with lymph node metastasis by conventional hematoxylin and eosin staining, 93% (53 of 57) had positive SNs, and the accuracy of nodal evaluation for metastasis was 99% (383 of 387). Only four false-negative SN biopsies were observed, and pathologic analysis revealed that three of those biopsies were pT2 or tumors > 4 cm. We observed no serious adverse effects related to endoscopic tracer injection or the SN mapping procedure. The endoscopic dual tracer method for SN biopsy was confirmed as safe and effective when applied to the superficial, relatively small gastric adenocarcinomas included in this study.

UR - http://www.scopus.com/inward/record.url?scp=84891589158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891589158&partnerID=8YFLogxK

M3 - Article

C2 - 24019550

AN - SCOPUS:84891589158

VL - 31

SP - 3704

EP - 3710

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 29

ER -